Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells

SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear. In this research, ApoE−/− mice were fed with western diet and empagliflozin wa...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Junping Li, Changping Li, Zhaoqi Huang, Chunling Huang, Juanzhang Liu, Tao Wu, Shuwan Xu, Peibiao Mai, Dengfeng Geng, Shuxian Zhou, Kun Zhang, Zhaoyu Liu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-11-01
Serie:	Frontiers in Pharmacology
Soggetti:	atherosclerosis arterial calcification empagliflozin osteogenic differentiation vascular smooth muscle cell
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1295463/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!